Literature DB >> 29794147

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Ramy Rahmé1, Lionel Ades1, Xavier Thomas2, Agnès Guerci-Bresler3, Arnaud Pigneux4, Norbert Vey5, Emmanuel Raffoux1, Sylvie Castaigne6, Olivier Spertini7, Sebastian Wittnebel8, Jean Pierre Marolleau9, Gandhi Damaj10, Dominique Bordessoule11, Julie Lejeune12, Sylvie Chevret12, Pierre Fenaux13.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29794147      PMCID： PMC6278967          DOI： 10.3324/haematol.2018.193151

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

Authors:  Lionel Adès; Sylvie Chevret; Emmanuel Raffoux; Stephane de Botton; Agnes Guerci; Arnaud Pigneux; Anne Marie Stoppa; Thierry Lamy; Francoise Rigal-Huguet; Anne Vekhoff; Sandrine Meyer-Monard; Frederic Maloisel; Eric Deconinck; Augustin Ferrant; Xavier Thomas; Nathalie Fegueux; Christine Chomienne; Herve Dombret; Laurent Degos; Pierre Fenaux
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

2.  Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Authors:  Uwe Platzbecker; Giuseppe Avvisati; Laura Cicconi; Christian Thiede; Francesca Paoloni; Marco Vignetti; Felicetto Ferrara; Mariadomenica Divona; Francesco Albano; Fabio Efficace; Paola Fazi; Marco Sborgia; Eros Di Bona; Massimo Breccia; Erika Borlenghi; Roberto Cairoli; Alessandro Rambaldi; Lorella Melillo; Giorgio La Nasa; Walter Fiedler; Peter Brossart; Bernd Hertenstein; Helmut R Salih; Mohammed Wattad; Michael Lübbert; Christian H Brandts; Mathias Hänel; Christoph Röllig; Norbert Schmitz; Hartmut Link; Chiara Frairia; Enrico Maria Pogliani; Claudio Fozza; Alfonso Maria D'Arco; Nicola Di Renzo; Agostino Cortelezzi; Francesco Fabbiano; Konstanze Döhner; Arnold Ganser; Hartmut Döhner; Sergio Amadori; Franco Mandelli; Gerhard Ehninger; Richard F Schlenk; Francesco Lo-Coco
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

3.  Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.

Authors:  R Rahmé; X Thomas; C Recher; N Vey; J Delaunay; E Deconinck; P Hirsch; D Bordessoule; J-B Micol; A Stamatoullas; C Mariette; C Pautas; P Bories; J-P Marolleau; M Hunault-Berger; N Fegueux; E Raffoux; H Dombret; L Degos; P Fenaux; L Adès
Journal:  Leukemia       Date:  2014-08-21       Impact factor: 11.528

4.  Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

Authors:  Miguel A Sanz; Pau Montesinos; Chelo Rayón; Alexandra Holowiecka; Javier de la Serna; Gustavo Milone; Elena de Lisa; Salut Brunet; Vicente Rubio; José M Ribera; Concha Rivas; Isabel Krsnik; Juan Bergua; José González; Joaquín Díaz-Mediavilla; Rafael Rojas; Félix Manso; Gert Ossenkoppele; José D González; Bob Lowenberg
Journal:  Blood       Date:  2010-04-14       Impact factor: 22.113

5.  Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.

Authors:  D Martínez-Cuadrón; P Montesinos; E Vellenga; T Bernal; O Salamero; A Holowiecka; S Brunet; C Gil; C Benavente; J M Ribera; M Pérez-Encinas; J De la Serna; J Esteve; V Rubio; J González-Campos; L Escoda; M E Amutio; M Arnan; J Arias; S Negri; B Lowënberg; M A Sanz
Journal:  Leukemia       Date:  2017-06-06       Impact factor: 11.528

6.  Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience.

Authors:  L Ades; S Chevret; S De Botton; X Thomas; H Dombret; B Beve; M Sanz; A Guerci; J S Miguel; J Dela Serna; C Garo; A M Stoppa; O Reman; A Stamatoulas; M Fey; J Y Cahn; J J Sotto; J H Bourhis; A Parry; C Chomienne; L Degos; P Fenaux
Journal:  Leukemia       Date:  2005-02       Impact factor: 11.528

7.  Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

Authors:  S Lehmann; A Ravn; L Carlsson; P Antunovic; S Deneberg; L Möllgård; A Rangert Derolf; D Stockelberg; U Tidefelt; A Wahlin; L Wennström; M Höglund; G Juliusson
Journal:  Leukemia       Date:  2011-04-19       Impact factor: 11.528

8.  Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

Authors:  Alan K Burnett; Nigel H Russell; Robert K Hills; David Bowen; Jonathan Kell; Steve Knapper; Yvonne G Morgan; Jennie Lok; Angela Grech; Gail Jones; Asim Khwaja; Lone Friis; Mary Frances McMullin; Ann Hunter; Richard E Clark; David Grimwade
Journal:  Lancet Oncol       Date:  2015-09-14       Impact factor: 41.316

Review 9.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo-Coco
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

10.  Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.

Authors:  Lionel Adès; Sylvie Chevret; Emmanuel Raffoux; Agnes Guerci-Bresler; Arnaud Pigneux; Nobert Vey; Thierry Lamy; Francoise Huguet; Anne Vekhoff; Jean-Francois Lambert; Bruno Lioure; Stephane de Botton; Erick Deconinck; Augustin Ferrant; Xavier Thomas; Bruno Quesnel; Bruno Cassinat; Christine Chomienne; Hervé Dombret; Laurent Degos; Pierre Fenaux
Journal:  Am J Hematol       Date:  2013-06-12       Impact factor: 10.047
View more
  1 in total

1.  Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.

Authors:  Lionel Adès; Pau Montesinos; Sabine Kayser; Ramy Rahmé; David Martínez-Cuadrón; Gabriel Ghiaur; Xavier Thomas; Marta Sobas; Agnes Guerci-Bresler; Ana Garrido; Arnaud Pigneux; Cristina Gil; Emmanuel Raffoux; Mar Tormo; Norbert Vey; Javier de la Serna; Olga Salamero; Eva Lengfelder; Mark J Levis; Pierre Fenaux; Miguel A Sanz; Uwe Platzbecker; Richard F Schlenk
Journal:  Leukemia       Date:  2020-02-19       Impact factor: 11.528
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.